JPRN-UMIN000004592Completed未知
Multicenter, placebo-controlled randomized trial for prevention of post ERCP pancreatitis with Risperidone - Tokyo P3R-2
Faculty of Medicine, University of Tokyo0 sites500 target enrollmentStarted: December 1, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with a history of ERCP. Patients with acute pancreatitis which need fasting therapy. Patients who have disseminated intravascular coagulation, sepsis, or acute circulatory failure. Patients with more severe disturbance of consciousness than Japan Coma Scale1-1. Patients who have severe heart disease, hepatic insufficiency, renal dysfunction, endocrine disease, or gastrointestinal tract disturbance. Pregnant or breast-feeding women. Women who have possibility of pregnancy or who are not willing to avoid pregnancy during the study. Patients who are treated with risperidone. Patients with severe hypersensitivity to risperidone Patients with mental illness or depression, who need drug therapy or can not comply with the protocol. Patients with Parkinson's disease or parkinsonism. Patients who have received banned drug within 2 weeks before ERCP Patients with chronic pancreatitis Patients who are judged inappropriate by chief (responsive) medical examiner
Investigators
Similar Trials
Active, not recruiting
Phase 1
Randomized, placebo-controlled multicenter trial of lithium plus treatment asusual (TAU) for acute suicidal ideation and behaviour in patients with suicidalmajor depressive episodeDiagnosis of a major depressive episodeinpatient at screening visitsuicidalideation/behaviour present defined by a clinical rating of = 8 on the SheehanSuicidality Tracking Scale (S-STS) at screening and a rating of =20 on the MontgomeryAsberg Depression Scale (MADRS) at both screening and baseline visitsbothgender, age =18 years.MedDRA version: 20.0Level: PTClassification code 10012397Term: Depression suicidalSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2013-000970-31-DETechnische Universität Dresden254
Active, not recruiting
Phase 2
Epicutaneous Immunotherapy for Milk AllergyFood allergy (milk)Food allergy, milk allergy, anaphylaxisT781JPRN-jRCTs041200024Takase Takafumi40
Active, not recruiting
Phase 1
AEUCTR2016-002072-26-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)450
Active, not recruiting
Phase 1
Will Lactoferrin supplements prevent infections in premature babies?ate onset invasive infection in very preterm infantsEUCTR2012-004260-22-GBniversity of Oxford2,203
Completed
Not Applicable
Multi-centre randomised placebo-controlled trial of corticosteroids in the prevention of coronary artery abnormalities in acute Kawasaki Disease (KD)ISRCTN74427627niversity of Leeds (UK)1,306